Phase III Study Evaluating the Efficacy and Safety of Lonsurf (trifluridine/tipiracil) in Patients with Metastatic Gastric Cancer Refractory to Standard Therapies (The TAGS Trial) Meets Primary Endpoint
Servier and Taiho Pharmaceutical Co., Ltd. announced today that the pivotal Phase III trial (TAGS) evaluating Lonsurf® (trifluridine/tipiracil) plus best supportive care (BSC) versus Placebo plus BSC in patients with advanced metastatic gastric cancer (mGC) met its primary objective to improve overall survival (OS).
These results will be submitted for presentation at an upcoming international medical conference and will be submitted to a peer-reviewed journal for publication.
The TAGS trial is a global, randomized, double-blind, placebo-controlled trial evaluating Lonsurf® versus Placebo in patients with pretreated metastatic gastric cancer (mGC).
The TAGS trial enrolled 507 patients who had received at least two prior regimens for mGC and who were refractory to, or unable to, tolerate further chemotherapy. Patients were randomized to receive Lonsurf® plus Best Supportive Care or placebo plus BSC in order to investigate the efficacy and safety. The primary endpoint is overall survival (OS) and secondary endpoint measures include progression free survival (PFS), safety and tolerability, as well as quality of life.
For more information on the TAGS trial, please visit https://clinicaltrials.gov/ct2/show/NCT02500043
The ClinicalTrials.gov Identifier is NCT02500043.
About Metastatic Gastric Cancer
Gastric cancer is the fifth most common cancer worldwide and the third most common cause of cancer-related death (after lung and liver cancer), with an estimate of 723,000 deaths annually1. Approximately 50% of patients with gastric cancer have advanced disease at the time of diagnosis2. Standard chemotherapy regimens for advanced gastric cancer include fluoropyrimidines, platinum derivatives, taxanes, ramucirumab or irinotecan. The addition of trastuzumab to chemotherapy is standard of care for patients with HER2-neu-positive advanced gastric cancer. However, after failure of first- and second-line therapies, standard third line treatments are limited.
Lonsurf® is an oral anticancer drug, comprising a combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity. Lonsurf® is registered in Japan, USA, European Union and in many other countries. In the European Union, Lonsurf is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan- based chemotherapies, anti-VEGF agents, and anti-EGFR agents.3
Lonsurf® is recommended by the National Institute for Health and Care Excellence (NICE).4 NCCN2 and ESMO Guidelines5 for the treatment of adult patients with metastatic colorectal cancer.
In June 2015, Servier and Taiho Pharmaceutical entered into an exclusive license agreement for the co-development and commercialization of Lonsurf®.
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 148 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,600 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs.
Becoming a key player in oncology is part of Servier’s long-term strategy. Currently, there are nine molecular entities in clinical development in this area, targeting gastric and lung cancers and other solid tumors, as well as different types of leukemia and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics, immune, cellular and targeted therapies, to deliver life-changing medicines to patients.
About Taiho Pharmaceutical Co., Ltd. (Japan)
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (https://www.otsuka.com/en/), is an R&D-driven specialty pharma focusing on the three fields of oncology, allergy and immunology, and urology. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts. In areas other than oncology as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people’s quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people’s efforts to lead fulfilling and rewarding lives.
For more information about Taiho Pharmaceutical, please visit: https://www.taiho.co.jp/en/
More information is available at: https://servier.com/en/
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr
2. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Gastric cancer. V.1.2018.
3. European Medicines Agency. EPAR Lonsurf. Available from: http://www.ema.europa.eu/ema/
4. NICE TA405. Available at: www.nice.org.uk/guidance/TA405
5. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: Van Cutsem E et al. Ann Oncol. 2016;27:1386-422
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ECAC EDS CB C3 Approval for Smiths Detection Technology23.10.2018 08:00 | Pressemelding
Smiths Detection has gained ECAC EDS CB C3 approval for the innovative HI-SCAN 6040 CTiX checkpoint scanner. This eliminates the need to remove electronic devices and liquids from hand luggage (subject to local authority guidelines) to make the process more passenger friendly. The HI-SCAN 6040 CTiX delivers the highest levels of security demanded by the new regulations, whilst optimizing checkpoint performance through improved productivity, a better passenger experience and lower operational costs. Removing the need to take out electronic devices and liquids from hand luggage means handling fewer trays which can significantly increase checkpoint throughput and the impressive 0.2m/s belt speed and low false alarm rate also speed up the process. “As the only technology meeting EDS CB C3 (and potentially future C4) standards, Computed Tomography (CT) is undoubtedly the way forward for checkpoint security,” commented Matt Clark, VP Technology & Product Development, Smiths Detection. “With
VIB 9–month profit before tax rises 176% YoY to VND 1,720 billion, Retail revenue increases 92% YoY23.10.2018 07:48 | Pressemelding
Vietnam International Bank (UPCoM: VIB) announced its financial statements of the first 9 months 2018 with positive results. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005507/en/ A clerk at VIB (Photo: Business Wire) Profit before tax grows 176% VIB reported profit before tax of VND 1,720 billion, up 176% year-on-year (YoY), equal to 86% of its full year target. The revenue increased by 48% YoY, in which interest income and non-interest income up 50% and 37% respectively; the latter accounted for 16% of total revenue and continued upward trend. The cost-to-income ratio (CIR) significantly dropped from 57% in 2017 to 48%. Provision expense in 9 months was lower than YoY in the context that VIB no longer has bad debts in VAMC. The return on equity ratio (ROE) reached 19.4%. The total asset of the bank reached over VND 132,500 billion, up 8% year-to-date; lending and deposits reached VND 95,200 billion and VND 89,200
Introducing The Continental Edge: The Easternmost Direct Interconnectivity Point Between Europe and the United States23.10.2018 07:00 | Pressemelding
Introducing the Continental Edge, the easternmost direct interconnection point between Europe and the United States. Four companies, focused on four key areas of services, have partnered to offer the first holistic solution that delivers best-of-breed colocation, connectivity, internet, and subsea cable solutions. The partnership is an amalgamation of companies brought to market collectivity by 1025Connect (for colocation); Aqua Comms (transatlantic subsea connectivity); DE-CIX (the leading Internet Peering Exchange), and Epsilon (a global network service provider providing on-demand SDN connectivity solutions). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005054/en/ The Continental Edge Map (Graphic: Business Wire) 1025Connect’s data center and colocation facilities serves as the central point where Aqua Comms' AEC-1 cable lands and Epsilon and DE-CIX platforms are available. Any customer connected to Epsilon’s lead
DataCo and SES Networks to Provide Broadband Network for APEC 201823.10.2018 06:50 | Pressemelding
Ahead of the 26th Asia-Pacific Economic Cooperation (APEC) forum taking place in Papua New Guinea, the PNG Government through its implementing agency, DataCo with the assistance of the Australian Government have chosen SES Networks to provide a managed data service delivering 6Gbps of high-bandwidth, low-latency connectivity to ensure the venues and all delegates have reliable, high-speed internet access during the conference from October to December 2018. SES announced that the service will utilise capacity from its O3b Medium Earth Orbit (MEO) satellite fleet to supplement existing capacity into Papua New Guinea (PNG) and will utilise existing DataCo infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181022006021/en/ DataCo and SES Networks to Provide Broadband Network for APEC 2018 (Photo: Business Wire) To provide additional connectivity to the nation, SES Networks has created a new core network for DataCo, f
MC2 Therapeutics Announces Topline Results Showing a Favorable Safety Profile and Reduction in Corneal Staining for MC2-03 in Dry Eye Patients with Moderate to Severe Keratitis23.10.2018 06:30 | Pressemelding
MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company, today announced topline results from the MC2-03-C1 Northern Lights Phase 2 trial evaluating the safety and efficacy of MC2-03 (PADciclo™) in moderate-to-severe dry eye (DED) patients. MC2-03 is an eye drop containing ciclosporin (CsA) formulated using MC2 Therapeutics’ proprietary PAD™ Technology to enable improved penetration into ocular tissues without the use of excipients that can cause ocular safety concerns. Topline results will be presented at the Ophthalmology Innovation Summit (OIS) in Chicago on October 25th, 2018. In this randomized, double-masked, parallel arms, controlled six-month trial enrolling 263 adult patients, two active treatment arms (MC2-03 0.06% CsA and MC2-03 0.03% CsA) were compared to two control arms (MC2-03 vehicle and lubricant) as an add-on therapy to a standard-of-care lubricant. The trial was powered to evaluate safety and efficacy of the individual treatment arms, and to potential
Secure Networks are Key to IoT Revolution, Says NTT Communications23.10.2018 06:00 | Pressemelding
While the Internet of Things (IoT) has the potential to drive the next wave of online innovation, it needs to be grounded on secure networks that prevent cyber criminals from hacking into the myriad of IoT-enabled devices that they are increasingly connecting. This is just one of the top line industry assessments provided today by NTT Communications Corp. (NTT Com), a company that owns and operates one of the world’s largest IP backbones and is the data and global IP service arm of Fortune 500 telecom leader NTT. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181022005985/en/ Michael Wheeler, executive vice president of NTT Communications Global IP Network at NTT America (Photo: Business Wire) IoT Has Massive Potential to Innovate, But First Needs to Be Secure “The Internet of Things revolution has tremendous potential to enhance and improve daily life by enabling our devices to connect and communicate with our other devices